Shorts trapped?

A new investment has this stock soaring                                                                                                                                                                                                                                                                                                                                                                                                                 November 06, 2023 [Follow JW on X]( I [Bishop on X]( I [Bond on X]( *Together with Indaptus Therapeutics, Inc. (Nasdaq: INDP) Good day, 360 – Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street! FOCUS LIST CREV - Up over 500% in pre-market after receiving $70 million in funding OGI - Up over 35% in pre after announcing a C$124.6 million equity investment from BAT (BTI) CLDX - Up over 25% in pre after Phase 1b trial success for itch and skin clearing treatment SPOTLIGHT *A Message on Behalf of Indaptus Therapeutics, Inc. (Nasdaq: INDP) 🔥 Hot Stock of the Day 🔥 Indaptus Therapeutics, Inc. (Nasdaq: INDP) This small-cap, early-stage NYC-based biotech company has been ripping higher this year. As of the close Friday, it’s up a whopping 62% year-to-date! On Monday of last week, the stock opened at $2.05, but by the close Friday, it had reached $2.50 — an incredible move more than 20% higher in just 5 days. For comparison, the SPY had one of its best moves in ages, and it “only” gained a little more than 5% on the week. These are the types of outsized moves we’re looking for. The question is: Will INDP’s run continue? We can’t know for sure, of course, but judging from what I see right now, I think last week’s 20% gain could just be the tip of the iceberg. Normally, I would think this type of move in one week would be the “top” for a stock, but as I look at multiple timeframes, I am seeing lots of bullish indicators from the algorithms, even with the recent rally. That, plus H.C. Wainwright's reiteration of its price target and news that there have been [no sales of stock]( by company insiders despite the stock run up has me excited about this company’s potential. And to add more fuel to the fire, INDP dropped even [more news]( this morning and the stock is on fire 🔥to start the day off! I encourage you to do your own due diligence – some great places to start including reading about their [lead indicator]( (Decoy20), recent [company press release](, [summary of the data](recently presented to the Society for Immunotherapy of Cancer and visiting the [company’s website](. *Sponsored by Sica Media. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results THE HOTLIST CREV - Up over 500% in pre-market after receiving $70 million in funding Carbon Revolution (CREV) is an OEM supplier and a leading global manufacturer of lightweight advanced technology carbon fiber wheels, and is based in Australia. The company’s stock began trading on Friday under the ticker symbol CREV after the reverse stock merger was completed. On Friday the stock closed up over 270% on its first day of trading under the new ticker. This morning, [the company announced]( that it has received an initial investment of US$70 million from a Structured Equity Facility of up to US$110 million from fund vehicles associated with Orion Infrastructure Capital ("OIC"), a leading infrastructure investment firm. The stock is now trading up over 500% in the pre-market this morning in wild trading post the reverse listing and news. The $200 level was support in the pre-market and now becomes an important area of potential resistance. Above it, targets to the upside are $240, $250, $280 and $300. Beyond that the pre-market high of $377.13 comes into play. Below $200, there is potential support at $150, $140, $100, $75 and $50 with a gap to fill at $29.32. Given the wild trading range risk management trading this stock is imperative. OGI - Up over 35% in pre after announcing a C$124.6 million equity investment from BAT (BTI) Organigram Holdings (OGI) through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. Earlier this morning [the company announced]( a C$124.6 million equity investment from BAT (BTI). BTI is a cigarette bran and vaping company increasingly focused on a growing range of reduced risk* tobacco and nicotine tobacco products (*these products are not risk free and are addictive). BAT employs over 50,000 people. The BAT Group generated revenue of £27.65 billion in 2022 and profit from operations of £10.5 billion. Partnering with such a large organization is a huge boost for OGI which according to Finviz.com had a market cap of only $93.38 million based on yesterday’s close. The stock is up over 35% after announcing the strategic investment. The $1.50 level was resistance in the pre-market and now becomes a potential area of support. Above it, targets to the upside are $1.60 and then the pre-market high at $1.66. Beyond that, $1.70, $1.90, $2, $2.10 and $2.40 come into play. Below $1.50 there is potential support at $1.40, $1.30, $1.25 and a gap to fill at $1.16. CLDX - Up over 25% in pre after Phase 1b trial success for itch and skin clearing treatment Celldex Therapeutics (CLDX) is a biopharmaceutical company that engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Over the weekend [the company announced]( phase 1b trial success for its itch and skin clearing treatment for its Barzolvolima. Then earlier this morning [the company released]( an additional announcement for its Phase 2 clinical trial of Barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines. The Phase 2 trial met its primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups. The stock is up over 25% in pre-market in reaction to the results. The $32 level found buyers so is now a potential area of support. Above it, targets to the upside are $34 and then the pre-market high at $38.90. Beyond that, $40, $42 and $44 come into play. Below $32, there is potential support at $31, $30, $28.50 and a gap to fill at $25.98 MARKET NEWS [Economic Calendar]( P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull Disclosures *PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising Indaptus Therapeutics, Inc. from a period beginning on November 6 through November 7, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Indaptus Therapeutics, Inc., increased trading volume, and possibly an increased share price of Indaptus Therapeutics, Inc.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Indaptus Therapeutics, Inc., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. [Ragingbull.com](, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2023 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America